European Lung Cancer Congress | Conference

Atezolizumab Regimen Improves OS After TKI Failure in EGFR+ NSCLC

April 14th 2019

Atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with EGFR-positive metastatic nonsquamous non–small cell lung cancer who have failed prior TKIs.

Dr. Reinmuth on Findings from the MYSTIC Study

April 13th 2019

Niels Reinmuth, MD, PhD, discusses the results of the MYSTIC study, which evaluated first-line durvalumab plus tremelimumab versus platinum-based chemotherapy in patients with metastatic non–small cell lung cancer.

Dr. Yang on Osimertinib as First-Line Therapy for EGFR-Positive NSCLC

April 13th 2019

James Chih-Hsin Yang, MD, discusses the final safety and efficacy results from 2 phase I expansion cohorts from the phase I/II AURA trial.

Mok Provides Pembrolizumab Update, Next Steps With Immunotherapy in NSCLC

April 13th 2019

Tony Mok, MD, discusses the KEYNOTE-042 trial and the implications of its findings, and sheds light on the evolving role of immunotherapy in non–small cell lung cancer.

Nivolumab/Ipilimumab Falls Short as Maintenance Therapy in SCLC

April 13th 2019

No overall survival advantage was obtained from maintenance therapy comprising nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) over placebo in patients with extensive-stage small cell lung cancer.

Ramalingam Discusses Osimertinib Efficacy and the Journey to Overcome Acquired Resistance

April 12th 2019

Suresh S. Ramalingam, MD, describes findings with osimertinib, and discusses the emerging body of data exploring primary and acquired resistance mechanisms to the third-generation agent.

Update Further Supports Osimertinib in Frontline EGFR+ NSCLC

April 12th 2019

Final results from 2 phase I expansion cohorts of frontline osimertinib (Tagrisso) presented at the 2019 European Lung Cancer Congress confirmed the efficacy of the third-generation TKI in patients with EGFR-positive non­–small cell lung cancer.

Dr. Reck on the Rationale of the Impower150 Study

April 12th 2019

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study.

Dr. Paz-Ares on Entrectinib in NTRK Fusion-Positive NSCLC

April 12th 2019

Luis G. Paz-Ares, MD, PhD, chief physician at the Hospital Universitario Doce De Octubre, discusses an integrated analysis of patients with NTRK fusion–positive non–small-cell lung cancer enrolled in the STARTRK-2, STARTRK-1, and ALKA-372-001 trials, which evaluated the safety and efficacy of entrectinib in patients with solid tumors.

Entrectinib Data Highlighted as FDA Weighs Approval for ROS1+ NSCLC

April 12th 2019

Patients with ROS1-positive non–small cell lung cancer showed high response rates and durable responses following treatment with entrectinib.

x